Lanean...
Deletion Mutations Keep Kinase Inhibitors in the Loop
Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common in...
Gorde:
| Argitaratua izan da: | Cancer Cell |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5028821/ https://ncbi.nlm.nih.gov/pubmed/27070691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.03.017 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|